v3.26.1
Restructuring, Impairment, and Related Charges, Net (Tables)
 3 Months Ended
Jun. 30, 2026
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring, Impairment, and Related Charges, Net
Restructuring, impairment, and related charges, net for the three months ended June 30, 2026 and 2025 consisted of the following:
Three Months Ended June 30, 2026
(In millions)
North
American Pharmaceutical (1)
Prescription Technology Solutions (1)
Medical-Surgical Solutions (1)
Corporate (1)
Total
Severance and employee-related costs, net $— $11 $14 $7 $32 
Exit and other-related costs (2)
1 10 9 37 57 
Asset impairments and accelerated depreciation1 40 — 6 47 
Total$2 $61 $23 $50 $136 
(1)Includes costs related to operational efficiencies and cost optimization efforts to support the Company’s North American Pharmaceutical segment, Prescription Technology Solutions segment, Medical-Surgical Solutions segment, and Corporate activities.
(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Three Months Ended June 30, 2025
(In millions)
North American Pharmaceutical (1)
Medical-Surgical Solutions (1)
Corporate (1)
Total
Severance and employee-related costs, net $— $5 $(1)$4 
Exit and other-related costs (2)
1 12 28 41 
Asset impairments and accelerated depreciation— — 2 2 
Total$1 $17 $29 $47 
(1)Includes costs related to operational efficiencies and cost optimization efforts to support the Company’s North American Pharmaceutical segment, Medical-Surgical Solutions segment, and Corporate activities.
(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Schedule of Activity Related to the Liabilities
The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the three months ended June 30, 2026:
(In millions)North American PharmaceuticalPrescription Technology SolutionsMedical-Surgical Solutions Corporate Total
Balance, March 31, 2026 (1)
$18 $3 $10 $13 $44 
Restructuring, impairment, and related charges, net2 61 23 50 136 
Non-cash charges(1)(40)— (6)(47)
Cash payments(3)— (16)(40)(59)
Balance, June 30, 2026 (2)
$16 $24 $17 $17 $74 
(1)As of March 31, 2026, the total reserve balance was $44 million, of which $30 million was recorded within “Other accrued liabilities” and $14 million was recorded within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.
(2)As of June 30, 2026, the total reserve balance was $74 million, of which $51 million was recorded within “Other accrued liabilities” and $23 million was recorded within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.